» Articles » PMID: 25608575

Cardiovascular Dysfunction in Patients with Liver Cirrhosis

Overview
Specialty Gastroenterology
Date 2015 Jan 23
PMID 25608575
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperdynamic syndrome is a well-known clinical condition found in patients with cirrhosis and portal hypertension, characterized by increased heart rate and cardiac output, and reduced systemic vascular resistance and arterial blood pressure. The leading cause of hyperdynamic circulation in cirrhotic patients is peripheral and splanchnic vasodilatation, due to an increased production/activity of vasodilator factors and decreased vascular reactivity to vasoconstrictors. The term "cirrhotic cardiomyopathy" describes impaired contractile responsiveness to stress, diastolic dysfunction and electrophysiological abnormalities in patients with cirrhosis without known cardiac disease. Underlying circulatory and cardiac dysfunctions are the main determinant in the development of hepatorenal syndrome in advanced cirrhosis. Moreover, the clinical consequences of cirrhosis-related cardiovascular dysfunction are evident during and after liver transplantation, and after transjugular intrahepatic portosystemic shunt insertion. Cardiovascular complications following these procedures are common, with pulmonary edema being the most common complication. Other complications include overt heart failure, arrhythmia, pulmonary hypertension, pericardial effusion, and cardiac thrombus formation. This review discusses the circulatory and cardiovascular dysfunctions in cirrhosis, examining the pathophysiologic and clinical implications in light of the most recent published literature.

Citing Articles

Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.

Ndakotsu A, Nduka T, Agrawal S, Asuka E Heart Fail Rev. 2025; .

PMID: 40069401 DOI: 10.1007/s10741-025-10500-7.


From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework.

Theodorakis N, Nikolaou M Biomolecules. 2025; 15(2).

PMID: 40001516 PMC: 11853431. DOI: 10.3390/biom15020213.


Immediate management of a cirrhosis-induced severe pericardial effusion: a case report and review of the literature.

Taheri M, Dargah A, Ramezani P, Anafje M, Nasrollahizadeh A, Ebrahimi P J Med Case Rep. 2025; 19(1):5.

PMID: 39780164 PMC: 11707975. DOI: 10.1186/s13256-024-05016-x.


The Assessment of Cardiovascular Abnormalities in Patients With Chronic Liver Disease: A Cross-Sectional Study.

Shah K, Kuruvada S, Gopalakrishnan M, Latchireddy B, Prathima T, Patra N Cureus. 2024; 16(11):e73311.

PMID: 39655150 PMC: 11626255. DOI: 10.7759/cureus.73311.


Evaluation of Cardiac Function in Children Undergoing Liver Transplantation.

Bansal N, Mahgerefteh J, Lamour J, Kogan-Liberman D, Ovchinsky M, Ganzburg K Pediatr Cardiol. 2024; .

PMID: 39576282 DOI: 10.1007/s00246-024-03673-9.


References
1.
Blendis L, Wong F . Is there a cirrhotic cardiomyopathy?. Am J Gastroenterol. 2000; 95(11):3026-8. DOI: 10.1111/j.1572-0241.2000.03249.x. View

2.
Northup P, Argo C, Shah N, Caldwell S . Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis. 2012; 32(1):39-48. DOI: 10.1055/s-0032-1306425. View

3.
Grace J, Klein S, Herath C, Granzow M, Schierwagen R, Masing N . Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology. 2013; 145(4):874-884.e5. DOI: 10.1053/j.gastro.2013.06.036. View

4.
Martell M, Coll M, Ezkurdia N, Raurell I, Genesca J . Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol. 2010; 2(6):208-20. PMC: 2999290. DOI: 10.4254/wjh.v2.i6.208. View

5.
Edens M, Kuipers F, Stolk R . Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev. 2009; 10(4):412-9. DOI: 10.1111/j.1467-789X.2009.00594.x. View